Key clinical point: An immunotherapy combination was superior to chemotherapy for prolonging overall survival.
Major finding: Median OS was 17.1 months with nivolumab plus ipilimumab vs. 14.9 months with chemotherapy (HR, 0.79; P = .007).
Study details: An open-label phase 3 randomized trial of 1,739 previously untreated patients with advanced/metastatic NSCLC.
Disclosures: The study was funded by Bristol-Myers Squibb. Dr. Peters reported a consultant/advisory role, speakers bureau activity and research support from BMS and others. Dr. Popat disclosed honoraria from BMS and others. Dr. Garrassino disclosed personal fees from BMS and others.
Hellmann MD et al. ESMO 2019. N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1910231.